CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE

N/A

Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

33,191 FDA adverse event reports analyzed

Last updated: 2026-04-14

About CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE

CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. The most commonly reported adverse reactions for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE include BREAST CANCER, BREAST CANCER FEMALE, BREAST CANCER METASTATIC, DRUG INEFFECTIVE, CEREBROVASCULAR ACCIDENT. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE.

Top Adverse Reactions

BREAST CANCER7,889 reports
BREAST CANCER FEMALE5,789 reports
BREAST CANCER METASTATIC1,506 reports
DRUG INEFFECTIVE725 reports
CEREBROVASCULAR ACCIDENT501 reports
DEPRESSION478 reports
HEADACHE422 reports
ANXIETY416 reports
NAUSEA408 reports
DEEP VEIN THROMBOSIS397 reports
FATIGUE390 reports
HOT FLUSH386 reports
PAIN381 reports
INSOMNIA378 reports
MYOCARDIAL INFARCTION378 reports
OESTROGEN RECEPTOR ASSAY POSITIVE375 reports
PULMONARY EMBOLISM354 reports
PROGESTERONE RECEPTOR ASSAY POSITIVE333 reports
BREAST CANCER IN SITU331 reports
MALAISE308 reports
OVARIAN CANCER307 reports
HYPERTENSION305 reports
DIZZINESS296 reports
THROMBOSIS294 reports
FEELING ABNORMAL286 reports
FALL266 reports
PAIN IN EXTREMITY261 reports
ARTHRALGIA256 reports
DYSPNOEA248 reports
WEIGHT INCREASED242 reports
ALOPECIA219 reports
DIARRHOEA215 reports
BACK PAIN212 reports
OFF LABEL USE198 reports
VAGINAL HAEMORRHAGE194 reports
VOMITING189 reports
MUSCLE SPASMS184 reports
ASTHENIA179 reports
WEIGHT DECREASED173 reports
CONDITION AGGRAVATED165 reports
CHEST PAIN163 reports
OSTEOARTHRITIS156 reports
GASTROOESOPHAGEAL REFLUX DISEASE151 reports
MIGRAINE143 reports
HYPERHIDROSIS140 reports
PRURITUS135 reports
BLOOD CHOLESTEROL INCREASED134 reports
COUGH134 reports
RASH134 reports
ABDOMINAL PAIN129 reports
OEDEMA PERIPHERAL129 reports
GAIT DISTURBANCE128 reports
ARTHRITIS127 reports
OSTEOPOROSIS123 reports
HYPOAESTHESIA122 reports
NIGHT SWEATS122 reports
CONSTIPATION120 reports
PNEUMONIA117 reports
INTENTIONAL PRODUCT MISUSE115 reports
MEMORY IMPAIRMENT114 reports
INJURY113 reports
FEMUR FRACTURE111 reports
PARAESTHESIA111 reports
NASOPHARYNGITIS108 reports
CARDIAC DISORDER106 reports
ABDOMINAL PAIN UPPER104 reports
PALPITATIONS104 reports
TREMOR104 reports
BREAST OPERATION103 reports
URINARY TRACT INFECTION103 reports
ANAEMIA102 reports
BREAST MASS102 reports
OVARIAN CANCER METASTATIC100 reports
PRODUCT QUALITY ISSUE100 reports
MYALGIA99 reports
BREAST CANCER RECURRENT98 reports
SINUSITIS95 reports
BLOOD PRESSURE INCREASED93 reports
VISION BLURRED93 reports
MASTECTOMY92 reports
ASTHMA90 reports
CONTRALATERAL BREAST CANCER90 reports
PRODUCT PRESCRIBING ERROR90 reports
DRUG HYPERSENSITIVITY89 reports
METRORRHAGIA89 reports
OSTEOPENIA88 reports
CORONARY ARTERY DISEASE87 reports
PYREXIA87 reports
ARTHROPATHY85 reports
DRUG DOSE OMISSION85 reports
ABDOMINAL DISTENSION84 reports
THERAPEUTIC RESPONSE UNEXPECTED83 reports
IRRITABILITY82 reports
INJECTION SITE PAIN80 reports
NERVOUSNESS80 reports
EMOTIONAL DISTRESS79 reports
DIABETES MELLITUS78 reports
DYSPEPSIA78 reports
HYPERSENSITIVITY78 reports
TRANSIENT ISCHAEMIC ATTACK78 reports

Report Outcomes

Out of 23,409 classified reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE:

Serious 84.7%Non-Serious 15.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female22,842 (99.8%)
Unknown35 (0.2%)
Male21 (0.1%)

Reports by Age

Age 57525 reports
Age 59504 reports
Age 55499 reports
Age 58492 reports
Age 61483 reports
Age 56477 reports
Age 60453 reports
Age 53447 reports
Age 54439 reports
Age 62404 reports
Age 64353 reports
Age 52338 reports
Age 63327 reports
Age 65292 reports
Age 51289 reports
Age 66282 reports
Age 50244 reports
Age 67238 reports
Age 68213 reports
Age 69208 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE?

This profile reflects 33,191 FDA FAERS reports that mention CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE?

Frequently reported terms in FAERS include BREAST CANCER, BREAST CANCER FEMALE, BREAST CANCER METASTATIC, DRUG INEFFECTIVE, CEREBROVASCULAR ACCIDENT, DEPRESSION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE?

Labeling and FAERS entries often list Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. in connection with CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.